Inari Medical, Inc.

Health Care
Medical/Dental Instruments
www.inarimedical.com

Earnings Score
Moat Score

Market Cap $2.97B
PE -38
Debt $NaN
Cash $41.21M
EV $NaN
FCF $5.37M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$78.58M
EBIT	-$53.36M
ROE	-18%
ROA	-8%
FCF	$5.37M
Equity	$434.76M
Growth Stability	-391%
PE	-37.8
PEG	-15.06
PB	6.83
P/FCF	553.12
P/S	5.17
Price/Cash	0.01
Net Margins	-17%
Gross Margins	87%
Op. Margins	-9%
Earnings CAGR	2%
Sales Growth YoY	21%
Sales Growth QoQ	5%
Sales CAGR	56%
FCF CAGR	3%
Equity CAGR	26%
Earnings Stability	-0.55
Earnings Growth YoY	-681%

Earnings Growth QoQ	-41%
Earnings CAGR 5Y	3%
Sales CAGR 5Y	58%
FCF CAGR 5Y	6%
Equity CAGR 5Y	28%
Earnings CAGR 3Y	30%
Sales CAGR 3Y	30%
FCF CAGR 3Y	-2%
Equity CAGR 3Y	12%
Market Cap	$2.97B
Revenue	$574.50M
Assets	$697.24M
Cash	$41.21M
Shares Outstanding	58.15M
Earnings Score	6%
Moat Score	4%
Working Capital	114.61M
Current Ratio	1.77
Gross Profit	$498.76M
Shares Growth 3y	6%
Equity Growth QoQ	3%
Equity Growth YoY	-4%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTreiver product is used for the treatment of pulmonary embolism. Geographically, the company has its presence across the United States.

SEC Filings

Direct access to Inari Medical, Inc. (NARI) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Inari Medical, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Inari Medical, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 2%

Stability -55%

loading chart...

Inari Medical, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Inari Medical, Inc..

Years

Calculation mode

= $66M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$5.4M	$5.5M	$5.7M	$5.9M	$6.1M	$6.3M	$6.4M	$6.6M	$6.8M	$7.1M	$7.3M	$73M
DCF		$5M	$4.7M	$4.4M	$4.1M	$3.9M	$3.6M	$3.4M	$3.2M	$3M	$2.8M	$28M
Value	$66M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-149%	-2%	10%	4%	-8%	-0%	-17%
ROA	-	2%	9%	3%	-5%	1%	-8%
ROE	-	3%	7%	4%	-7%	-0%	-18%

Bad Net Margins (-16.71%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-2.49	-	-	-	-	-
Debt over Equity	-	-0.51	-	-	-	-	-
Growth Stability	-	-	-	100%	-391%	-	-391%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (-391%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	649%	173%	98%	38%	29%	58%
Earnings YoY growth	-	-88%	-1K%	-29%	-397%	-94%	3%
Equity YoY growth	-	-1%	-612%	19%	74%	11%	28%
FCF YoY growth	-	-31%	-56%	-434%	-302%	-230%	6%